J 2018

Relationship between TRAIL and Left Ventricular Ejection Fraction in Patients with ST-Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention

TERINGOVA, Elena, Martin KOZEL, Jiri KNOT, Viktor KOCKA, Klára BENEŠOVÁ et. al.

Basic information

Original name

Relationship between TRAIL and Left Ventricular Ejection Fraction in Patients with ST-Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention

Authors

TERINGOVA, Elena (203 Czech Republic), Martin KOZEL (203 Czech Republic), Jiri KNOT (203 Czech Republic), Viktor KOCKA (203 Czech Republic), Klára BENEŠOVÁ (203 Czech Republic, belonging to the institution) and Petr TOUSEK (guarantor)

Edition

Biomed Research International, New York, Hindawi Publishing Corporation, 2018, 2314-6133

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

20801 Environmental biotechnology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 2.197

RIV identification code

RIV/00216224:14110/18:00104050

Organization unit

Faculty of Medicine

DOI

UT WoS

000439234000001

Keywords in English

ST-Elevation Myocardial Infarction Treated

Tags

Tags

International impact, Reviewed
Změněno: 31/10/2019 11:56, Mgr. Michal Petr

Abstract

V originále

Background. Apoptosis plays an important role in the myocardial injury after acute myocardial infarction and in the subsequent development of heart failure. Aim. To clarify serum kinetics of apoptotic markers TRAIL and sFas and their relation to left ventricular ejection fraction (LVEF) in patients with ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (pPCI). Methods. In 101 patients with STEMI treated with pPCI, levels of TRAIL and sFas were measured in series of serum samples obtained during hospitalization and one month after STEMI. LVEF was assessed at admission and at one month. Major adverse cardiovascular events (MACE, i.e., death, re-MI, and hospitalization for heart failure and stroke) were analysed during a two-year followup. Results. Serum level of TRAIL significantly decreased one day after pPCI (50.5pg/mL) compared to admission (56.7pg/mL), subsequently increased on day 2 after pPCI (58.8pg/mL), and reached its highest level at one month (70.3pg/mL). TRAIL levels on days 1 and 2 showed a significant inverse correlation with troponin and a significant positive correlation with LVEF at baseline. Moreover, TRAIL correlated significantly with LVEF one month after STEMI (day 1: r 0.402, p<0.001; day 2: r 0.542, p<0.001). On the contrary, sFas level was significantly lowest at admission (5073pg/mL), increased one day after pPCI (6370pg/mL), and decreased on day 2 (5548pg/mL). Significantly highest sFas level was marked at one month (7024pg/mL). sFas failed to correlate with LVEF at baseline or at one month. Both TRAIL and sFas showed no ability to predict improvement of LVEF one month after STEMI or a 2-year MACE (represented by 3.29%). Conclusion. In STEMI treated with pPCI, TRAIL reaches its lowest serum concentration after reperfusion. Low TRAIL level is associated with worse LVEF in the acute phase of STEMI as well as one month after STEMI. Higher TRAIL level appears to be beneficial and thus TRAIL seems to represent a protective mediator of post-AMI injury.